Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTx-011
- Development stage
- Unknown
- Lead developer
- Nuclide Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
NTx-011 is a therapeutic radiopharmaceutical being developed by Nuclide Therapeutics for the treatment of therapy-resistant solid tumors. The drug candidate consists of a therapeutic radionuclide conjugated to a small-molecule targeting agent, designed to deliver cytotoxic radiation directly to tumor cells. While the specific biological target and the identity of the radionuclide isotope have not been publicly disclosed by the sponsor, the program is positioned to address advanced malignancies that have failed standard-of-care therapies. As of 2024, NTx-011 is the lead asset in Nuclide Therapeutics' pipeline and is in Phase 0/1 clinical development.
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on NTx-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTx-011.